Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of 2-dose versus 3-dose Cervarix vaccination 6.5 years after primary study HPV-048
2014-000060-17Phase 3Terminated
- Sponsor
- GSK
- Start
- Mar 2014
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of human papillomavirus type 16 L1 capsid protein antigen in human papillomavirus infection, Cervical Cancer (CC), Vulval carcinoma and 4 more (2 cohorts), sponsored by GSK. Primary endpoint: Immune persistence 6.5 years after first vaccination. Started Mar 2014; status: terminated.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigen
03
Conditions
human papillomavirus infectionCervical Cancer (CC)Vulval carcinomavaginal cancercervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2014-000060-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000060-17.